Drug Profile
mTORC1 inhibitor programme II - Adicet Bio
Alternative Names: Mechanistic target of rapamycin complex 1 pathway inhibitor programme II - Adicet Bio; mTOR pathway inhibitor - Adicet Bio; TORC1 Inhibitor - Adicet BioLatest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Novartis
- Developer Adicet Bio
- Class
- Mechanism of Action MTORC1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Immunodeficiency disorders
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for research development in Immunodeficiency-disorders in USA
- 15 Sep 2020 Adicet Bio has been merged with resTORbio to form Adicet Bio
- 23 Feb 2018 9233822 - crosschecked, no updates